Preserving tissue in near-complete rectal cancer response
Part of Cancer, Digestive system clinical trials.
This trial studies whether it’s safe to preserve the rectum (instead of removing it right away) for people with locally advanced rectal cancer who respond very well after pre-treatment radiation and/or chemotherapy. It may help some patients avoid major surgery, but eligibility depends on response seen on exam, scope, and MRI, and on having no spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer confirmed by a pathology (tissue) test called adenocarcinoma.
- You received treatment before surgery: radiation and/or chemoradiation (radiation with chemotherapy).
- About 8 weeks after that treatment, tests must show a complete or near-complete response based on exam, endoscopy (scope of the rectum), and MRI scan.
- There must be no evidence that the cancer has spread to distant organs (no distant metastases).
- You must have had the response assessed using digital rectal exam and flexible rectoscopy, plus MRI (all part of the study checks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines chemotherapy, immunotherapy, and radiation before surgery for patients with middle or low rectal cancer. The goal is to shrink the tumor enough to avoid removing the anus, preserving bowel function.
This trial compares two ways to preserve the rectum/avoid major surgery after radiation: a focused contact x-ray treatment versus waiting longer and then removing only a small area if needed. It may help some people keep more normal bowel function while still controlling the cancer.
This study looks at how well people with rectal cancer do over time when they try to keep their rectum instead of having surgery. It is for patients who have already had chemoradiation and whose tumor has shrunk to a small scar (2 cm or less).
This trial tests a strategy to avoid surgery by using watchful waiting after initial treatment for early-stage rectal cancer. It may help patients keep their rectum and avoid a permanent colostomy.
This Phase 2 trial tests a “total neoadjuvant” treatment plan (medicine given before surgery) that may help some people avoid or reduce surgery for very low rectal cancer. It aims to improve the chance of keeping more normal function while still treating the cancer safely.
This trial tests a program that helps you and your doctor decide together whether to avoid surgery and keep your rectum after chemo and radiation. It's for people with early-stage rectal cancer who have not had prior treatment for this cancer.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.